EPO 2026 Revised Examination Guidelines Enter Force, Streamlining Procedural Guidance

The European Patent Office put its 2026 consolidated Guidelines for Examination into effect on April 1, superseding the April 2025 editions and folding two long-standing reference publications, the European Patent Guide and the Euro-PCT Guide, into the unified framework. The former guides will remain accessible only through May 31, 2026, leaving patent prosecutors, in-house counsel, and corporate IP teams a narrow window to adjust workflows before the older materials are withdrawn entirely.

The revision is not a cosmetic update. Two Enlarged Board of Appeal decisions now codified in the guidelines carry immediate consequences for applicants across technology sectors. Under G 1/24, claim interpretation at the EPO now systematically requires examiners to consult the description and drawings in all cases, not merely when claim language is ambiguous. For U.S. companies accustomed to drafting broad, self-contained claims, the shift means that specification language will more directly constrain claim scope during examination and opposition, making careful description drafting a front-line prosecution concern rather than a fallback.

For biotech and pharmaceutical applicants, the codification of G 1/23 rewrites the novelty calculus around selection inventions. The guidelines now confirm that marketed products and their analyzable properties form part of the state of the art, abandoning the prior case-law-derived tests that had offered applicants a more lenient novelty standard for selecting sub-ranges or specific compounds from prior art disclosures. A new chapter on sufficiency of disclosure for further medical use claims, added to Part F, adds another layer of scrutiny that life sciences filers must account for at the drafting stage.

The 2026 edition also carries the EPO's first formal guidance on artificial intelligence in patent prosecution. The office made clear that parties bear full responsibility for AI-assisted filings, and it instructed practitioners to carefully review any EPO minutes generated using AI tools against their own detailed notes, since AI, the guidelines noted, is often unable to correctly summarize complex legal topics. That framing positions the EPO cautiously as AI drafting tools become standard in firm workflows, and it signals that reliance on AI-generated procedural documents will not transfer liability away from the applicant or representative.

On procedure, the 2026 guidelines abolish accelerated search under the Programme for Accelerated Prosecution of European Patent Applications, known as PACE, a change formalized in section E-VIII, 4. Companies that previously counted on PACE to compress examination timelines for competitive technology products will need to recalibrate expectations. The elimination arrives as parallel national rules on AI-related inventions and standard-essential patent essentiality assertions continue to diverge across jurisdictions, making consolidated EPO guidance more valuable precisely when harmonization is hardest to achieve.

The EPO published the revised documents in its three official languages, in both clean and annotated versions showing recent modifications, alongside a complete list of amended sections with direct hyperlinks. A public consultation running through April 3, 2026, collects practitioner feedback via an anonymized webform; the SACEPO Working Party on Guidelines will review submissions in May, with the results informing the 2027 editions. Patent law firms have begun circulating detailed reviews of the amended sections, with implementation memos expected in the days ahead.